Quercetin, one of the major flavonoids in plants, has been recently reported to have neuroprotective effects against neurodegenerative processes. However, since the molecular signaling mechanisms governing these effects are not well clarified, we evaluated quercetin's effect on the neuroprotective signaling events in dopaminergic neuronal models and further tested its efficacy in the MitoPark transgenic mouse model of Parkinson's disease (PD). Western blot analysis revealed that quercetin significantly induced the activation of two major cell survival kinases, protein kinase D1 (PKD1) and Akt in MN9D dopaminergic neuronal cells. Furthermore, pharmacological inhibition or siRNA knockdown of PKD1 blocked the activation of Akt, suggesting that PKD1 acts as an upstream regulator of Akt in quercetin-mediated neuroprotective signaling. Quercetin also enhanced cAMP response-element binding protein phosphorylation and expression of the cAMP response-element binding protein target gene brain-derived neurotrophic factor. Results from qRT-PCR, Western blot analysis, mtDNA content analysis, and MitoTracker assay experiments revealed that quercetin augmented mitochondrial biogenesis. Quercetin also increased mitochondrial bioenergetics capacity and protected MN9D cells against 6-hydroxydopamine-induced neurotoxicity. To further evaluate the neuroprotective efficacy of quercetin against the mitochondrial dysfunction underlying PD, we used the progressive dopaminergic neurodegenerative MitoPark transgenic mouse model of PD. Oral administration of quercetin significantly reversed behavioral deficits, striatal dopamine depletion, and TH neuronal cell loss in MitoPark mice. Together, our findings demonstrate that quercetin activates the PKD1-Akt cell survival signaling axis and suggest that further exploration of quercetin as a promising neuroprotective agent for treating PD may offer clinical benefits.
Although the etiology of PD is not fully understood, the involvement of oxidative stress and mitochondrial dysfunction are strongly indicated in its pathogenesis (Cardoso et al. 2005; Schapira 2008) , with impaired mitochondrial biogenesis contributing to the mitochondrial dysfunction (Zheng et al. 2010; Youdim and Oh 2013) . Therefore, stimulation of mitochondrial biogenesis can provide neuroprotection against dopaminergic neurodegeneration in PD.
Although toxin-based models have been widely used as animal models of PD, they do not fully recapitulate the human PD pathology. Furthermore, the acute nature of toxin-based models of PD limits their usefulness in PD drug development and in studying the compensatory cell survival mechanisms which might occur in PD patients during the course of the disease. The MitoPark model was recently developed as an animal model of PD by inactivating TFAM in dopaminergic neurons using the Cre-loxP system (Ekstrand et al. 2007 ). The MitoPark mouse recapitulates several aspects of human PD, such as adult onset, progressive degeneration of dopaminergic neurons, and responsiveness to levodopa . Thus, the MitoPark mouse represents a useful pre-clinical model for testing potential neuroprotective agents for the treatment of PD.
Quercetin is a natural polyphenol, found abundantly in vegetables and fruits, and is the main flavonoid in our daily diet (Hertog et al. 1995) . Quercetin has therapeutic potential for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and PD because of its antioxidant and anti-inflammatory properties and its ability to cross the blood-brain barrier (Ansari et al. 2009; Haleagrahara et al. 2011; Ishisaka et al. 2011) . Indeed, recent studies have shown that quercetin exerts neuroprotective effects in toxin-based models of PD (Haleagrahara et al. 2011; Lv et al. 2012) . Moreover, a previous study reported that quercetin mitigated the loss of complex-I activity induced by rotenone (Karuppagounder et al. 2013) . However, the molecular mechanisms of quercetin-induced neuroprotection have not been well clarified. The aim of our present study was to unravel the molecular mechanisms underlying the neuroprotective effect of quercetin and to evaluate its neuroprotective efficacy against the progressive neurodegenerative process in the MitoPark mouse model of PD. Our results demonstrate that quercetin activates the protein kinase D1 (PKD1) and Akt pro-survival signaling axis, stimulates mitochondrial biogenesis, and increases mitochondrial bioenergetics capacity in dopaminergic neuronal cells. More importantly, quercetin protects against dopaminergic neurodegeneration in the progressively degenerative MitoPark mouse model of PD. Overall, our results suggest that quercetin is a promising neuroprotective drug candidate that deserves further pre-clinical and clinical evaluations for the treatment of PD.
Materials and methods
Chemicals and reagents 6-hydroxydopamine (6-OHDA), anti-b-actin antibody (Cat# A5441 RRID:AB_476744; Sigma-Aldrich), propylene glycol, vitamin B3, vitamin C, and folic acid were purchased from Sigma-Aldrich (St. Lois, MO, USA). Quercetin was provided by Dr Joshua Selsby (Iowa State University, Department of Animal Sciences). The Bradford protein assay kit was purchased from Bio-Rad (Hercules, CA, USA). Antibodies against PKD1 (Cat# sc-639 RRID: AB_2172392), a-tubulin (Cat# sc-5286 RRID:AB_628411), BDNF (Cat# sc-546 RRID:AB_630940), and TFAM (Cat# sc-23588 RRID:AB_2303230) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to phospho PKD1 [p-S744/ 748 (Cat# 2054S RRID:AB_2172539; Danvers, MA, USA) and p-S916 (Cat# 2051S RRID:AB_330841)], phospho-Akt (p-S473) (Cat# 4060 also 4060L, 4060S, 4060P RRID:AB_2315049), total Akt (Cat# 4691 also 4691L, 4691P, 4691S RRID:AB_915783), total cAMP response-element binding protein (CREB) (Cat# 9197 also 9197S, 9197L RRID:AB_331277), and phospho-CREB (p-S133) (CST Cat# 9198 also 9198S, 9198L RRID:AB_2561044) were obtained from Cell Signaling Technology. Anti-PGC-1a antibody (Cat# AB3242 RRID:AB_2268462; Millipore) was purchased from Millipore (Billerica, MA, USA). Lipofectamine 2000 reagent, Alexa 680-conjugated anti-mouse secondary antibody (Cat# A-21057 RRID:AB_2535723; Thermo Fisher Scientific, Waltham, MA, USA) and all cell culture reagents were obtained from Invitrogen (Carlsbad, CA, USA). IRDye 800-conjugated antirabbit secondary antibody (Cat# 611-745-127 RRID:AB_1057615; Rockland) was purchased from Rockland Labs (Gilbertsville, PA, USA).
Cell cultures
The mouse dopaminergic MN9D cell line (RRID:CVCL_M067), a kind gift from Dr Syed Ali (National Center for Toxicological Research/Food and Drug Administration, Jefferson, AR), was cultured as described previously . Briefly, MN9D cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units penicillin, and 50 lg/mL streptomycin and maintained at 37°C in a 5% CO 2 atmosphere. The rat mesencephalic dopaminergic cell line, referred to as N27 cells, was kindly provided by Dr Kedar N. Prasad (University of Colorado Health Sciences Center, Denver, CO, USA). N27 cells (Cat# SCC048, RRID:CVCL_D584; Millipore) were cultured as described previously (Anantharam et al. 2002; Asaithambi et al. 2014) .
Transient transfections, reporter gene assays, and RNAi Transient transfections of MN9D cells were performed using Lipofectamine 2000 reagent according to the manufacturer's protocol, as described previously . The 3.1-kb mouse PGC-1a promoter construct was a generous gift from Dr Zhen Yan (University of Virginia School of Medicine). Cells were seeded into 12-well plates at a density of 15 9 10 4 cells/well 1 day before transfection. Each transfection was performed with 1 lg of reporter constructs along with 0.2 lg of pcDNA3-LacZ to normalize transfection efficiencies. In quercetin experiments, indicated doses of quercetin were added 24 h after transfection. Cells were harvested 24 h after treatment, lysed in 150 lL of Reporter Lysis Buffer (Promega, Madison, WI, USA), and assayed for luciferase activity. Luciferase activity was measured on a Synergy 2 MultiMode Microplate Reader (BioTek, Winooski, VT, USA) using the luciferase assay system (Promega). Luciferase activities were normalized to b-galactosidase activity. To silence PKD1 expression, transfection of small interfering RNAs (siRNAs) was conducted using the Lipofectamine 2000 reagent. The PKD1-specific package of four siRNAs (GS18760) was purchased from Qiagen (Valencia, CA, USA), and scrambled (negative control) siRNA (4611) was obtained from Ambion (Austin, TX, USA). Forty-eight hours after transfection, cells were treated with 10 lM quercetin for 24 h. Western blot was used to assess the extent of PKD1 expression knockdown.
Quantitative real-time RT-PCR Total RNA was isolated from cells using the Absolutely RNA Miniprep kit (Stratagene, La Jolla, CA, USA), and 1-2 lg RNA was used to generate cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed on an Mx300P qPCR system (Stratagene) using the RT 2 SYBR Green qPCR Mastermix kit (Qiagen) and QuantiTect Primer Assay kit (Qiagen). All RT-qPCR reactions were performed in triplicate and normalized to b-actin housekeeping gene; PCR conditions are available upon request. Dissociation curves were run to verify the singularity of the PCR product. Data were analyzed using the comparative threshold cycle (Ct) method.
Quantitative real-time PCR analysis of mtDNA content MN9D cells were plated in six-well plates at a density of 3 9 10 5 cells/well. Twenty-four hours later, cells were treated with 10 and 30 lM quercetin for 24 h. Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's protocol. We determined mtDNA content by quantitative real-time PCR with SYBR green. Briefly, 10 ng nuclear DNA and 1 ng mitochondrial DNA were amplified using the primers for mitochondrial cytochrome b and nuclear b-actin genes. Reactions were performed using an Mx300P qPCR system (Stratagene).
MitoTracker assay MN9D cells were plated in 96-well plates at a density of 1 9 10 4 cells/well. After 24 h, cells were treated with 10 and 30 lM quercetin for 24 h. Cells were then washed with serum-free medium and incubated with 200 nM MitoTracker Green FM (Invitrogen) for 30 min. After this, cells were triple-washed with phosphate-buffered saline, and then fluorescence was read on a fluorescence microplate reader (excitation 485 nm, emission 520 nm).
Western blot analysis
After treatments, cells or brain tissues were collected and resuspended in a modified radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors. The Bradford assay was performed to determine protein concentrations (Bradford 1976) . Briefly, lysates containing equal amounts of protein were loaded in each lane and separated on a 10-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane (Bio-Rad). The membranes were blocked in LI-COR blocking buffer for 1 h at RT. Antibodies directed against PKD1 (1 : 1000), phospho-PKD1 (1 : 1000) (Asaithambi et al. 2011; Ay et al. 2015) , Akt (1 : 1000), phospho-Akt (1 : 1000) (Gordon et al. 2016) , TFAM (1 : 1000) (Gordon et al. 2016) , PGC-1a (1 : 1000) (Saleem et al. 2014) , CREB (1 : 1000), phospho-CREB (1 : 1000) (Devi and Ohno 2015) , and BDNF (1 : 500) (Chen et al. 2015) were incubated with the membranes overnight at 4°C. Western blot was performed using IRDye 800 anti-rabbit, Alexa Fluor 680 goat anti-mouse, and Alexa Fluor 680 donkey anti-goat secondary antibodies. Western blot images were captured and analyzed with an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE, USA).
Cell viability assay
Cell viability was analyzed using the Muse Annexin V and Dead Cell Kit (Millipore) according to manufacturer's instructions. This assay utilizes Annexin V to label phosphatidylserine on the cell membrane surface of apoptotic cells. The dead cell marker 7-aminoactinomycin D was also used as an indicator of cell membrane integrity. MN9D cells were plated in six-well plates at a density of 3 9 10 5 cells/well. Twenty-four hours later, cells were pre-treated with 10 lM quercetin for 1 h and then co-treated with 50 lM 6-OHDA for 24 h. After treatment, cells were collected and resuspended in culture medium. Next, 100 lL of Muse Annexin V and dead cell reagent (Millipore) and 100 lL of culture medium containing 3 9 10 4 cells were mixed and incubated for 20 min in the dark. Viable and apoptotic cells were analyzed using the Muse Cell Analyzer (Millipore).
Measurement of mitochondrial oxygen consumption
The Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) was used to measure oxygen consumption rate (OCR) in N27 dopaminergic neuronal cells as described previously (Charli et al. 2016) . Briefly, N27 cells were seeded at 10,000 cells/well in a Seahorse Bioscience polystyrene microplate. Twenty-four hours later, cells were treated with 1 and 10 lM quercetin for 24 h. After treatment, cells were changed to assay media and the N27 cells-containing culture plates were loaded into the Seahorse instrument to collect baseline OCR measurements. The experimental agents oligomycin (1 lg/mL), carbonyl cyanide-4-phenylhydrazone (FCCP, 3 lM), and antimycin A (10 lM) were injected using the included ports on the XF96 cartridges and OCR measurements were collected. Basal OCR, ATP-linked OCR, maximal OCR, and spare respiratory capacity were calculated, as described previously (Dranka et al. 2010) .
Animals and treatment
MitoPark transgenic mice were kindly provided by Dr Nils-Goran Larsson of Karolinska Institute, Stockholm. All mice used for this study were from the MitoPark breeding colony at Iowa State University. Mice were housed under standard conditions of constant temperature (22 AE 1°C), humidity (relative, 30%), a 12-h light cycle, and free access to food and water. Animal care and protocol procedures were approved and supervised by the Institutional Animal Care and Use Committee (IACUC) at Iowa State University (Ames, IA, USA). We used male and female animals in our studies. We obtained realistic estimates of error variance of 15% for biochemical and neurochemical endpoints and 20% for histological measures. Using this information and setting the Type I error rate to a = 0.05 and power to 80%, we calculated sample sizes (n) of 8-10 for each group, which has worked well for us in previous animal studies conducted in our laboratory (Ghosh et al. 2013; Gordon et al. 2016) . All mice were pre-screened for normal baseline performance during behavioral assessments conducted prior to randomly assigning animals to experimental groups. To randomly assign mice to the treatment groups described below, we opened the Random Integer Generator (https://www.random.org/integers/) in two separate browser windows, one to generate a random integer for group (1, 2) and one for animal (1-16 in Experiment 1, or 1-18 in Experiment 2) under the constraint of equal group size (n = 8 or 9 per group, respectively). Investigators involved with data collection and analysis were not blinded to group allocation. In our first animal study (n = 8/group), 12-week-old MitoPark and C57BL/6 control mice were gavaged with either 25 mg/kg quercetin or vehicle solution (5% dimethyl sulfoxide in corn oil) for 6 weeks. In our second animal study (n = 9/group), 12-week-old MitoPark and C57BL/6-LC mice were treated via oral gavage for 8 weeks either with vehicle (50% propylene glycol) or QB3C comprising quercetin (175 mg/kg), vitamin B3 (7 mg/kg), vitamin C (175 mg/kg), and folic acid (140 lg/kg). The QB3C formulation has been shown to have better bioavailability than quercetin (Jin et al. 2010; Knab et al. 2011; Casuso et al. 2013) . After treatment, mice were subjected to behavioral, neurochemical, biochemical, and histological measurements. C57BL/6-LC are littermate controls from our MitoPark breeding colony.
High-performance liquid chromatography (HPLC)
Striatal dopamine, dihydrophenylacetic acid (DOPAC), and homovanillic acid (HVA) levels were quantified using HPLC with electrochemical detection. Samples were prepared and quantified as described previously (Gordon et al. 2016) . Briefly, striatal tissue weight was measured and then neurotransmitters from the tissues were extracted in 0.1 M perchloric acid containing 0.05% Na 2 EDTA and 0.1% Na 2 S 2 O 5 ; isoproterenol was used as an internal standard. Dopamine, DOPAC, and HVA were separated isocratically using a C-18 reversed phase column with a flow rate 0.6 mL/ min. An HPLC system (UltiMate 3000, Dionex, Madison, WI, USA) with a thermostatted autosampler (WPS-3000TSL, Dionex) was used for these experiments. The electrochemical detection system consisted of a coulometric array detector (CoulArray 5600A, Dionex) with a guard cell (model 5020, Thermo Scientific, Chelmsford, MA, USA) and an analytical cell (model 5014B, ESA Inc., Chelmsford, MA, USA) set to potentials of 350, 0, À150, and 220 mV. The data acquisition and analysis were performed using CoulArray Data Station 3.10 software (ESA, Inc.) . Neurotransmitter values were expressed as ng per mg of striatal tissue.
3,3 0 -diaminobenzidine (DAB) immunostaining
Tyrosine hydroxylase (TH)-3,3 0 -diaminobenzidine immunostaining was performed in striatal and substantia nigral sections, as described previously (Ghosh et al. 2010) . Briefly, mice were perfused with 4% paraformaldehyde and post-fixed with paraformaldehyde and 30% sucrose. The fixed brains were cut into 30-lm coronal sections and kept in 30% sucrose-ethylene glycol solution at À20°C. On the day of staining, sections were washed with phosphate-buffered saline and incubated with anti-TH antibody (1 : 1600, Calbiochem, Billerica, MA, USA) overnight at 4°C. Next, sections were incubated for 1 h at RT with biotinylated anti-rabbit secondary antibody. Nissl-positive neurons were stained with cresyl violet. Total number of TH + neurons in every sixth section of the SN were counted stereologically with Stereo Investigator software (MBF Bioscience, Williston, VT, USA), as described previously (Gordon et al. 2016) .
Behavioral measurements
An automated open-field apparatus (AccuScan, Columbus, OH, USA) was used to measure the locomotor activity of mice, as described previously in our publications (Ghosh et al. 2010 (Ghosh et al. , 2016 Gordon et al. 2016) . The rotarod test was performed to evaluate motor coordination and balance of mice using an acceleration profile (from 4 rpm to 60 rpm within 180 s). Before treatments, mice were trained for two consecutive days. One day prior to killing, open-field and rotarod experiments were conducted. Locomotor activities were recorded for 10 min. Data were collected and analyzed using the VersaPlot and VersaDat software.
Statistical analysis
All in vitro data were determined from at least two biologically independent experiments, each done with a minimum of three biological replicates. Data analysis was performed using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA), first via oneway ANOVA and then by the Tukey multiple comparison test for statistical comparisons. Differences with p ≤ 0.05 were considered significant.
Results
Quercetin stimulates the phosphorylation of pro-survival kinases PKD1 and Akt in dopaminergic neuronal cells We recently reported that activation of protein kinase D1 (PKD1) protects dopaminergic cells from oxidative stressinduced cell death (Asaithambi et al. 2011 (Asaithambi et al. , 2014 . Therefore, in the first set of experiments, we examined whether quercetin activates the pro-survival kinase PKD1. We treated mouse dopaminergic MN9D cells with non-toxic doses (Fig. S1 ) of quercetin (0.3-30 lM) for 24 h. Quercetin treatment significantly activated PKD1 as measured by the phosphorylation of both activation loop (S744/748) and autophosphorylation (S916) sites of PKD1 ( Fig. 1a and b) . Next, we wanted to examine the effect of quercetin on Akt, another pro-survival kinase with a neuroprotective role against dopaminergic neurodegeneration (Ries et al. 2006) . Treatment of MN9D cells with the same concentration range of quercetin for 24 h induced a significant concentrationdependent increase in Akt phosphorylation ( Fig. 1c and d) .
To uncover the interrelationship between PKD1 and Akt prosurvival kinases during quercetin treatment, we utilized the pharmacological PKD1-specific inhibitor CID755673 (Sharlow et al. 2008; Torres-Marquez et al. 2010) . CID755673 (50 lM) had no effect in untreated MN9D cells when added alone. In contrast, pre-treatment with 50 lM CID755673 significantly suppressed the phosphorylation of Akt induced by quercetin (Fig. 1e) . To further validate the results obtained from pharmacological inhibitor studies, we adopted an RNAi approach. We transfected MN9D cells either with scrambled siRNA or PKD1-siRNA for 48 h to knockdown PKD1 expression before treating with 10 lM quercetin for 24 h. Quercetin treatment activated Akt in the control cells, whereas PKD1 knockdown effectively inhibited this activation (Fig. 1f) . Taken together, these results suggest that quercetin can activate PKD1 and Akt pro-survival kinases in dopaminergic cells, and that PKD1 is an upstream regulator of Akt survival signaling activated by quercetin.
Quercetin induces expression of the CREB target gene BDNF
The CREB is a transcriptional activator of the neurotrophic factor BDNF, which is particularly relevant to PD (Tao et al. 1998; Yang et al. 2008; Jourdi et al. 2009) , and its activity is regulated by the phosphorylation of S133 (Johannessen et al. 2004) . Therefore, we examined whether quercetin augments CREB signaling and the levels of BDNF. We exposed MN9D cells to various doses of quercetin (0.3-30 lM) and determined the levels of CREB phosphorylation at serine 133 and BDNF protein expression by Western blot analysis. As shown in Fig. 2a , quercetin enhanced CREB phosphorylation and BDNF expression in a dose-dependent manner. Next, we treated MN9D cells with 10 and 30 lM quercetin for 24 h to determine whether the quercetininduced BDNF protein expression is attributable to the transcriptional activation of BDNF gene. Real-time RT-PCR analysis showed a dose-dependent increase in BDNF mRNA levels, indicative of up-regulation of the BDNF gene by quercetin (Fig. 2b) . Together, these results suggest that quercetin up-regulates BDNF gene expression in dopaminergic neuronal cells possibly through CREB phosphorylation.
Quercetin stimulates mitochondrial biogenesis in MN9D dopaminergic neuronal cells To further explore the effect of quercetin on dopaminergic neuronal cells, we determined whether quercetin induces mitochondrial biogenesis in MN9D cells. First, we determined the effect of quercetin on peroxisome proliferatoractivated receptor-gamma coactivator 1-alpha (PGC-1a) expression since PGC-1a functions as a key regulator of mitochondrial biogenesis and is highly expressed in tissues with high energy demands, including skeletal muscle, brown fat, heart, and brain (Wu et al. 1999; Tritos et al. 2003) . We transfected MN9D cells with PGC-1a promoter-reporter construct, and then 24 h post-transfection, we treated cells with 1 and 10 lM quercetin for 24 h. Quercetin (10 lM) significantly increased PGC-1a promoter activity, but 1 lM quercetin showed only a minimal effect on PGC-1a promoter activity (Fig. 3a) . Therefore, we selected 10-30 lM concentration of quercetin for further studies related to PGC-1a transcription. Since CREB is known to enhance PGC-1a transcription (Herzig et al. 2001) , we examined whether CREB is involved in quercetin-induced PGC-1a promoter activation. We transfected MN9D cells either with wild-type PGC-1a promoter (pPGC-1a-WT) or PGC-1a promoter with a mutation in the CRE site (pPGC-1a-DCRE) (Akimoto et al. 2008) , and then 24 h post-transfection, we treated cells with quercetin for 24 h. Interestingly, the quercetin-induced PGC-1a promoter activation was abolished when the CRE site was mutated (Fig. 3b) , suggesting quercetin regulates PGC-1a transcriptional activity through CREB. PGC-1a mRNA (Fig. 3c) and protein ( Fig. 3d ) levels were also significantly up-regulated in quercetinexposed MN9D cells. The mRNA expression of the mitochondrial biogenesis markers cytochrome B (Fig. 4a) and TFAM (Fig. 4b) (Struewing et al. 2007; Li et al. 2011) , as well as TFAM protein levels ( Fig. 4c and d) were also significantly up-regulated in the MN9D cells treated with 10 and 30 lM quercetin. To further confirm that quercetin can stimulate mitochondrial biogenesis, we assessed mitochondrial content of quercetin-treated cells by MitoTracker assay. Our results revealed that 10 and 30 lM quercetin treatment significantly increased mitochondrial mass in MN9D cells (Fig. 4e) . We also determined mtDNA copy number using mitochondrial cytochrome b and nuclear b-actin genes and found that 10 and 30 lM quercetin treatment significantly increased mtDNA content in MN9D cells (Fig. 4f) . Collectively, these results clearly demonstrate that quercetin can stimulate mitochondrial biogenesis in dopaminergic neuronal cells.
Quercetin increases mitochondrial bioenergetics capacity in N27 dopaminergic cells After establishing that quercetin induces mitochondrial biogenesis, we examined the effect of quercetin on cellular bioenergetics in N27 dopaminergic neuronal cells. MN9D and N27 dopaminergic cell lines share many characteristics of dopaminergic neurons and are often used interchangeably in many laboratories, including our own. We treated N27 cells with 1 and 10 lM quercetin for 24 h and measured OCR using Seahorse technology. Basal OCR was measured first, followed by the sequential addition of oligomycin, FCCP, and antimycin A to measure mitochondrial function ( Fig. 5a ) (Dranka et al. 2011) . Importantly, quercetin significantly enhanced mitochondrial oxygen consumption, as evidenced by increases in basal OCR, ATP-linked respiration, maximal OCR, and spare respiratory capacity ( Fig. 5a-e) . Basal and ATP-linked respiration also increased in MN9D cells in response to quercetin (Fig. S2 ). These data suggest that quercetin treatment increases mitochondrial bioenergetic efficiency in dopaminergic neuronal cells.
Quercetin reduces 6-OHDA-induced neurotoxicity in MN9D cells As described above, our results demonstrated that quercetin can effectively induce activation of pro-survival kinases PKD1 and Akt and mitochondrial biogenesis. To further confirm the neuroprotective effect of quercetin, MN9D cells were pre-treated with 10 lM quercetin for 1 h and then cotreated with the dopaminergic neurotoxicant 6-OHDA (50 lM) for 24 h. Apoptosis and cell viability were measured by flow cytometry. As expected, 6-OHDA alone substantially reduced cell viability (Fig. 6a-c) ; however, pretreatment with quercetin significantly reduced the total number of apoptotic cells while increasing the number of live cells when compared to 6-OHDA alone. These results demonstrate that quercetin protects MN9D cells against 6-OHDA-induced cell death in vitro.
Quercetin protects against dopaminergic neurodegeneration in MitoPark mice
After confirming that quercetin has a neuroprotective effect in dopaminergic neuronal cell cultures, the next logical step was to test our in vitro findings in an in vivo model of PD. We adopted the chronic MitoPark mouse model that recapitulates key features of the progressive neurodegenerative process in PD (Ekstrand et al. 2007; Galter et al. 2010) . In our preliminary animal study, MitoPark and C57BL6 control mice were gavaged with either 25 mg/kg quercetin or vehicle from age 12 to 18 weeks. Quercetin reduced motor deficits (Fig. 7a-c ) and striatal dopamine depletion (Fig. 7d) in MitoPark mice. Since previous studies suggested that combining quercetin with vitamins C, B3, and folic acid improves quercetin bioavailability (Quindry et al. 2008; Jin et al. 2010; Knab et al. 2011; Casuso et al. 2013 ),
we then opted to test the efficacy of the QB3C formulation in MitoPark mice. Twelve-week-old MitoPark and littermate control (C57BL/6-LC) mice were treated either with vehicle or the quercetin-containing formulation QB3C daily via oral gavage for 8 weeks (Fig. 7e) . As expected, a significant loss of TH + dopaminergic neurons in the SN and TH + terminals in the striatum was observed in MitoPark mice (Fig. 7f) . Importantly, QB3C treatment significantly reduced nigrostriatal degeneration (Fig. 7f) and increased the number of TH + neurons in the SN of MitoPark mice (Fig. 7g) . Furthermore, QB3C significantly restored striatal dopamine (Fig. 8a) , DOPAC (Fig. 8b) , and HVA (Fig. 8c ) levels in MitoPark mice. Collectively, these results demonstrate that quercetin can slow down the progressive degeneration of dopaminergic neurons in the MitoPark mouse model of PD.
Quercetin ameliorates motor deficits in MitoPark mice
After observing the neuroprotective effect of QB3C against nigrostriatal degeneration, we evaluated whether QB3C for 24 h and stained with 200 nM MitoTracker Green FM, which was detected on a fluorescence microplate reader (n = 6). Values represented as percentage of the activity of control and are expressed as the means AE SEM of two independent experiments performed in triplicate comparing control and quercetin-treated groups (***p < 0.001). (f) MN9D cells were treated with 10 and 30 lM quercetin for 24 h. Genomic DNA was isolated and mtDNA content was determined by quantitative PCR with SYBR green (n = 6). Primers for mitochondrial cytochrome B and nuclear b-actin genes were used to amplify 10 ng nuclear DNA and 1 ng mitochondrial DNA. Values represented as percentage of the activity of control and are expressed as the means AE SEM of three independent experiments performed in duplicate comparing control and quercetin-treated groups (**p < 0.01; ***p < 0.001).
treatment improves behavioral deficits in MitoPark mice. By 12 weeks of age, MitoPark mice begin showing motor deficits relative to age-matched control mice (Ekstrand et al. 2007) . Eight weeks after QB3C treatment and 1 day prior to killing, locomotor activity and rotarod performance of MitoPark mice were measured using a Versamax activity monitor and a rotarod instrument. As shown in representative maps (VersaPlot) tracking movements, the locomotor activity of MitoPark mice significantly decreased (Fig. 9a) . On the other hand, QB3C treatment significantly improved locomotion in MitoPark mice. Consistently, QB3C reversed the decreases in movement time (Fig. 9b) , total distance (Fig. 9c) , and the number of movements (Fig. 9d) of MitoPark mice. Moreover, MitoPark mice treated with QB3C spent significantly more time on the rotarod than did vehicle-treated MitoPark mice (Fig. 9e) . Collectively, these findings suggest that quercetin improves motor function in the MitoPark mouse model of PD.
Discussion
In this study, we investigated the molecular mechanisms underlying quercetin-mediated dopaminergic neuroprotection and tested the efficacy of quercetin in the MitoPark mouse model of PD. Our study demonstrates that quercetin can activate the pro-survival kinases PKD1 and Akt and induces the expression of BDNF in dopaminergic neuronal cells. Furthermore, we show that quercetin increases mitochondrial biogenesis and bioenergetics capacity in cell culture models of PD. More importantly, we observed that quercetin protects against progressive nigrostriatal degeneration, striatal dopamine depletion, and behavioral deficits in MitoPark mice. Quercetin is one of the main flavonoids in our daily diet and has been recognized for having a myriad of pharmacological effects, including anti-oxidant, antiviral, antibacterial, anti-inflammatory, and anti-carcinogenic properties (Duthie and Dobson 1999; Ramos et al. 2006; Boots et al. 2008; Zandi et al. 2011) . Several lines of evidence suggest that quercetin has therapeutic potential for the prevention and treatment of different human diseases, including neurodegenerative diseases (Ansari et al. 2009; Egert et al. 2009; Haleagrahara et al. 2011; Chakraborty et al. 2014; SabogalGuaqueta et al. 2015) . Although recent studies have documented the neuroprotective effect of quercetin in toxin-based models of PD, the molecular mechanisms behind the protective effect of quercetin are not well-understood (Haleagrahara et al. 2011; Lv et al. 2012) . In this study, Fig. 5 Effect of quercetin on mitochondrial respiration rate in N27 dopaminergic cells. (a-e) N27 dopaminergic neuronal cells were treated with 1 and 10 lM quercetin for 24 h and the N27 cellcontaining culture plates were loaded into the Seahorse XF96 analyzer for oxygen consumption rate (OCR) measurement. Mitochondrial dynamics were measured using the sequential injection of oligomycin A (1 lg/mL), FCCP (1 lM), and antimycin A (10 lM) (a). Basal OCR (b), ATP-linked respiration (c), maximal OCR (d), and spare respiratory capacity (e) were calculated from the output OCR values (n = 6). Values expressed as the means AE SEM of three independent experiments performed in duplicate comparing control and quercetin-treated groups (**p < 0.01; ***p < 0.001).
we first investigated the effect of quercetin on the prosurvival kinases PKD1 and Akt in dopaminergic neuronal cells. We recently reported that PKD1 plays an anti-apoptotic role in dopaminergic neurons exposed to oxidative stress (Asaithambi et al. 2011; Ay et al. 2015) . The protective role of Akt has been documented for neurodegenerative diseases, including PD (Humbert et al. 2002; Ries et al. 2006; Zhang et al. 2010) . Ries et al. showed that viral over-expression of Akt in the SN significantly protected against 6-OHDAinduced neurodegeneration (Ries et al. 2006) . In addition, treatment of mice with the Parkinsonian neurotoxicant MPTP led to a significant reduction in phospho-Akt levels (Durgadoss et al. 2012), pointing to the pro-survival role of Akt in dopaminergic neurons. Our results show that quercetin can effectively activate PKD1 and Akt kinases in dopaminergic neuronal cells (Fig. 1a-d) . We then investigated the downstream and upstream relationships between PKD1 and Akt. Previously, it was shown that PKD3, another isoform of the PKD family, regulates Akt signaling in prostate cancer cells . In our experiments, we found that pharmacological inhibition or siRNA-mediated knockdown of PKD1 reduces quercetin-induced Akt phosphorylation ( Fig. 1e and f) , suggesting that PKD1 might function upstream of Akt kinase during quercetin treatment in dopaminergic cells. Since PKD1 can directly phosphorylate CREB at Ser133 (Johannessen et al. 2007) , we further studied the phosphorylation status of CREB in quercetintreated cells. CREB regulates the expression of genes involved in neuroprotection (Shieh et al. 1998; Meller et al. 2005; Barneda-Zahonero et al. 2012) . Once CREB gets phosphorylated at Ser133, the CREB-binding protein binds to CREB and facilitates transcription of cAMP response element (CRE)-dependent genes including BDNF (Tao et al. 1998; Lonze and Ginty 2002) . In our experiments, we show that quercetin increases CREB phosphorylation (Fig. 2a) and also up-regulates BDNF protein and mRNA expression in MN9D dopaminergic neuronal cells (Fig. 2a and b) . Importantly, we observed that pre-treatment with quercetin significantly attenuates 6-OHDA-induced neurotoxicity (Fig. 6a-c) . Of note, a previous study reported that quercetin (15 lg/mL, approx. 50 lM) induced 50% cell death in primary neurons (Jakubowicz-Gil et al. 2008) , while another study showed that quercetin decreased cell viability at a higher concentration (1 mM) in PC12 cells (Ahn and Jeon 2015) . However, the quercetin concentrations that we used in our study (0.3-30 lM) did not cause any cell death in MN9D dopaminergic neuronal cells (Fig. S1) . Together, these data suggest that quercetin can protect dopaminergic cells against neurotoxic insults and that the PKD1/CREB/ BDNF axis might mediate the protective effect of quercetin in dopaminergic neuronal cells.
Mitochondria play a pivotal role in the fate of neurons and mitochondrial dysfunction has been recognized as an important contributor to the neurodegenerative process observed in PD (Olanow and Tatton 1999; Onyango 2008) . Previous studies have also shown that impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in PD (Zheng et al. 2010; Youdim and Oh 2013) . PGC-1a is a transcriptional coactivator that regulates mitochondrial biogenesis and antioxidant defenses (Clark and Simon 2009) . Zheng et al. (2010) performed a comprehensive genomewide meta-analysis by combining nine genome-wide expression studies of 410 PD patients and healthy controls and found that genes regulated by PGC-1a are under expressed in PD patients (Zheng et al. 2010) . Moreover, PGC-1a activity declines through the loss of parkin function and binding of alpha-synuclein to its promoter (Shin et al. 2011; Siddiqui et al. 2012) , suggesting that decreased PGC-1a expression may play a role in PD pathogenesis. Therefore, we next checked whether quercetin can enhance mitochondrial biogenesis in dopaminergic cells. We found that quercetin increased PGC-1a promoter activity, mRNA, and protein expression in MN9D cells (Fig. 3a-d) . Of note, mutation of the CRE site in the PGC-1a promoter abolished quercetininduced promoter activation (Fig. 3b) , suggesting that quercetin acts through CREB to induce PGC-1a expression. Previous studies have also shown that CREB binds to the consensus CRE site in the PGC-1a promoter and positively regulates PGC-1a transcription in neuronal cells (Cui et al. 2006; Liu et al. 2014) . We also found that quercetin treatment increased expression of other marker genes for mitochondrial biogenesis, namely cytochrome B and TFAM, in MN9D cells (Fig. 4a-d) . TFAM is required for mtDNA replication and transcription and is also known to play a role in mtDNA maintenance and integrity (Scarpulla 2008; Ngo et al. 2011) . Furthermore, we found increases in mitochondrial mass (Fig. 4e ) and mtDNA content (Fig. 4f ) in MN9D cells treated with quercetin, suggesting that quercetin can effectively enhance mitochondrial biogenesis in dopaminergic cells. Next, we measured the effect of quercetin on cellular bioenergetics and found that quercetin significantly increased mitochondrial OCR in dopaminergic cells (Fig. 5a-e ). Our results demonstrate that quercetin can serve as an effective natural compound to improve mitochondrial function and biogenesis in dopaminergic neuronal cells.
To further substantiate the neuroprotective effects of quercetin, we used the MitoPark transgenic animal model of PD. The MitoPark model was previously developed by specific inactivation of TFAM in dopaminergic neurons (Ekstrand et al. 2007) . We recognize that a number of potentially neuroprotective agents showing apparent antiParkinsonian effects in pre-clinical studies have failed to show any neuroprotective effect in humans. One reason for their failure in clinical trials is the lack of good animal models of PD for translational research. We tested the neuroprotective efficacy of quercetin in MitoPark mice because they represent the most severe mouse model for recapitulating several key features of PD in humans, such as adult-onset degeneration of nigrostriatal dopamine circuitry and the progressive course of phenotypic manifestations and neurodegeneration (Ekstrand et al. 2007; Gubellini and Kachidian 2015) . The motor performance of these mice remained similar to their age-matched controls until the age of 12 weeks. However, from 12 weeks of age onward, MitoPark mice begin to display impaired locomotor activity accompanied by a progressive loss of dopaminergic neurons in the SN and a coincident reduction in striatal dopamine. In our study, 12-week-old MitoPark mice were treated with the quercetin-containing formulation QB3C for 8 weeks. Our results show that quercetin reversed TH neuronal cell loss ( Fig. 7f and g ), the depletion of striatal dopamine and its metabolites (Fig. 8a-c) , and behavioral deficits (Fig. 9a-e) in MitoPark mice, suggesting that quercetin has the potential to slow down the progression of disease. It is noteworthy that the antioxidant vitamins B3, C, and folic acid in our QB3C formulation have been shown to be protective in experimental models of PD. However, very high doses of these antioxidants were necessary to achieve their protective Twelve-week-old MitoPark and C57BL6-LC littermate mice were treated either with vehicle (50% propylene glycol) or QB3C via oral gavage for 8 weeks. Locomotor activities were measured using a VersaMax system and a rotarod instrument 1 day prior to being killed. Representative maps tracking the movements of mice (a). Group analysis of movement time (b), Distance travelled (c), number of movements (d), and time spent on rotarod (e). Values expressed as means AE SEM of nine mice per group (*p < 0.05; **p < 0.01).
effects. For example, 5 mM vitamin B3 was required to protect against the loss of dopaminergic neurons in parkinmutant flies (Lehmann et al. 2016) . Similarly, high doses of nicotinamide (250-500 mg/kg) are required to be beneficial in MPTP-induced animal models (Anderson et al. 2006; Xu et al. 2012) . Another study showed that dietary supplementation with a high-dose of folic acid (4 mM) can enhance mitochondrial function in pink1-mutant flies (Tufi et al. 2014) . In contrast, our QB3C formulation contains only 7 mg/kg vitamin B3, 140 lg/kg folic acid, and 175 mg/kg vitamin C. Furthermore, the protective role of vitamin C in PD remains controversial since one epidemiological study found a decreased risk of PD in individuals consuming diets rich in vitamin C (Fahn 1992) , whereas other studies showed no effects or even an increased risk of PD with consumption of vitamin C (Scheider et al. 1997; Zhang et al. 2002; Etminan et al. 2005; Seidl and Potashkin 2011) . Although we cannot completely rule out a positive effect, we contend that the concentrations of vitamins B3, C, and folic acid that we used in the QB3C formulation are too low to show any protective effects in our study.
Although one previous study reported that 100-250 mg/kg quercetin increased caspase-3 activity in the mouse liver and brain (Choi and Kim 2010) , many more studies suggest that quercetin is safe even at very high concentrations (950 mg/kg and 3000 mg/kg) (Barrenetxe et al. 2006; Harwood et al. 2007; Ruiz et al. 2009 ). Another recent study showed that exercise, but not quercetin, improved mitochondrial biogenesis in soleus muscles, but they used only 10 mg/kg quercetin in their study (Kwon et al. 2014) . In our study, we observed that quercetin showed only a modest protective effect in MitoPark mice, possibly because of the fact that the MitoPark mouse is the most severe model of PD. Indeed, although the MitoPark model has been used since 2007 to test the efficacy of various interventions, only a few compounds have shown neuroprotective effects in MitoPark mice (Langley et al., 2017 , Marcellino et al. 2010 . MitoPark mice show changes in electrophysiological parameters and dopamine signaling, even prior to 12 weeks when the onset of motor symptoms occurs (Good et al. 2011; Branch et al. 2016) , which is when we started treating the animals in this study. Our treatment paradigm, in which we administered quercetin after the diagnosis of motor systems, mimics the clinical approach. Therefore, starting the quercetin treatment of MitoPark mice at an early age may yield greater neuroprotection.
In summary, we demonstrate for the first time that quercetin can effectively activate PKD1 pro-survival signaling in dopaminergic cells. Quercetin also induces Akt and CREB phosphorylation and BDNF expression. Our results suggest that the PKD1/CREB/BDNF axis may at least partially mediate the neuroprotective effects of quercetin. Moreover, quercetin treatment increases mitochondrial biogenesis in dopaminergic neurons. Importantly, quercetin protects against dopaminergic neurodegeneration in the MitoPark transgenic mouse model of PD. Our findings clearly suggest that quercetin is a promising neuroprotective agent and merits further investigation for the prevention and treatment of neurodegenerative diseases, including PD.
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